Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?

Bahçecíoglu, Ömer Faruk; Gök, Selim; Durmus, Mefküre

Bahçecíoglu, Ömer Faruk; Gök, Selim; Durmus, Mefküre.

Bahçecíoglu ÖF; Clinical Pharmacy, Inonu University, Malatya, Turkey omerfb92@hotmail.com.
Gök S; Clinical Pharmacy, Inonu University, Malatya, Turkey.
Durmus M; Clinical Pharmacy, Inonu University, Malatya, Turkey.

Eur J Hosp Pharm ; 28(2): e6, 2021 03.

Article in English | MEDLINE | ID: covidwho-1388525

Subject(s)

COVID-19 Drug Treatment; Chemical and Drug Induced Liver Injury; ATP Binding Cassette Transporter, Subfamily B; Adenosine Monophosphate/analogs & derivatives; Alanine/analogs & derivatives; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors/adverse effects; Humans; SARS-CoV-2

Keywords

COVID-19; drug monitoring; drug substitution; drug-related side effects and adverse reactions; metabolic side effects of drugs and substances

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Chemical and Drug Induced Liver Injury / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Eur J Hosp Pharm Year: 2021 Document Type: Article Affiliation country: EJHPHARM-2021-002680

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google